New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - sodium valproate 100 mg/ml - solution for injection - 100 mg/ml - active: sodium valproate 100 mg/ml excipient: dibasic sodium phosphate dodecahydrate monobasic potassium phosphate water for injection - the treatment of patients with epilepsy or bipolar disorder, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - ropivacaine hydrochloride 2 mg/ml - solution for infusion - 2 mg/ml - active: ropivacaine hydrochloride 2 mg/ml excipient: hydrochloric acid nitrogen sodium chloride sodium hydroxide water for injection - surgical analgesia - epidural block for surgery, including caesarean section - intrathecal block - major nerve block - field block (minor nerve block and infiltration)

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; water for injections; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: dibasic sodium phosphate dodecahydrate; nitrogen; water for injections; monobasic potassium phosphate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate; nitrogen - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: nitrogen; dibasic sodium phosphate dodecahydrate; monobasic potassium phosphate; water for injections - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefazolin sodium 1.048 g equivalent to 1 g cefazolin - powder for injection - 1 g - active: cefazolin sodium 1.048 g equivalent to 1 g cefazolin - cefazolin-aft is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infection: due to s. pneumoniae, klebsiella sp, h. influenzae, staph, aureus (including penicillinase-producing strains), and group a ?-haemolytic streptococci. injectable penicillin g benzathine is considered to be the medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin-aft is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefazolin sodium 524mg equivalent to 500 mg cefazolin - powder for injection - 500 mg - active: cefazolin sodium 524mg equivalent to 500 mg cefazolin - cefazolin-aft is indicated in the treatment of the following serious infections due to susceptible organisms: respiratory tract infection: due to s. pneumoniae, klebsiella sp, h. influenzae, staph, aureus (including penicillinase-producing strains), and group a ?-haemolytic streptococci. injectable penicillin g benzathine is considered to be the medicine of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefazolin-aft is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cephazolin in the subsequent prevention of rheumatic fever are not available at present.